6 March 2018 | 10:00 – 14:15

EPQT®- An Alternative to the Thorough QT Trial 
Maidenhead Office Park
Westacott Way
Littlewick Green
Maidenhead SL6 3QH, UK

Covance respects your Privacy.
Manage your Subscriptions.
© Copyright 2018 Covance Inc. All rights reserved.
Please complete the information below to register for the workshop.
10:00        Introduction

10:15        Overview of EPQT® and Changes in the Regulatory Landscape
                          Dr. Borje Darpo, Chief Scientific Officer, iCardiac

11:00        Coffee Break

11:15        Early Precision QT Modelling in a Rare Disease Setting: 
                        the Selisistat First-in-Human Study - Clinical and Regulatory Considerations
                        Goran Westerberg, PhD, MTOPRA, Associate Professor
                        Owner, LaCrocina Pharmaceutical Consultants

12:00        Lunch and Demo of EPQT® Data Collection

13:00        Overview of Leeds Clinical Research Unit 
                        Raymond Donninger, MB ChB, MBA
                        Covance Clinical Pharmacology Leeds

13:45        Q&A Session with Expert Panel

14:15        Closing Remarks